Alprostadil (Caverject/MUSE) Anesthesia and Perioperative Interaction

What Is Alprostadil and Why Does It Matter in the Perioperative Period?

Alprostadil is a synthetic prostaglandin E1 (PGE1) that relaxes smooth muscle in penile vasculature and the systemic arterial bed. Delivered either as a Caverject intracavernosal injection (doses of 2.5 to 40 mcg) or a MUSE intraurethral pellet (125 to 1,000 mcg), it produces erection by increasing local cyclic AMP, dilating cavernosal arteries, and relaxing trabecular smooth muscle [1]. Systemic absorption is real: up to 80% of an intraurethral dose reaches systemic circulation within 10 to 20 minutes [2].

That systemic load matters in the operating room. Anesthetic agents independently reduce sympathetic tone and vascular resistance. Alprostadil on board adds a second vasodilatory vector, raising the likelihood of intraoperative hypotension from additive to potentially multiplicative in susceptible patients.

How Alprostadil Is Cleared

Alprostadil's plasma half-life is 5 to 10 minutes. The lungs extract roughly 68% of circulating PGE1 in a single pass [3]. Metabolites (13,14-dihydro-15-keto-PGE1 and related compounds) retain some vasodilatory activity and are renally excreted over 60 to 90 minutes [4]. Patients with renal impairment (eGFR <30 mL/min) clear these metabolites more slowly, prolonging pharmacodynamic exposure.

Systemic Absorption by Route

• Intracavernosal (Caverject): plasma peak at 30 to 60 minutes post-injection; systemic levels low but detectable [1].
• Intraurethral (MUSE): faster and larger systemic absorption due to urethral vascularity; symptomatic hypotension rate approximately 3.3% vs. 1.0% for intracavernosal in clinical trials [2].

The Core Perioperative Hazard: Additive Hypotension

Volatile anesthetics (sevoflurane, desflurane, isoflurane) reduce mean arterial pressure (MAP) by 20 to 30% through direct myocardial depression and peripheral vasodilation [5]. Propofol induction similarly drops systolic blood pressure by 25 to 40% in healthy adults [6]. Neuraxial anesthesia (spinal or epidural) blocks sympathetic outflow, producing venous pooling and a fall in systemic vascular resistance that can exceed 30% [7].

Alprostadil acts through a separate receptor pathway (EP2/EP3 prostanoid receptors and IP receptors on vascular smooth muscle) but arrives at the same endpoint: lower vascular resistance [3]. Simultaneous action of both mechanisms is not simply additive in a linear sense; case series and pharmacological modelling suggest the combination can produce a MAP reduction greater than either agent alone in patients with baseline cardiovascular compromise [8].

Reported Clinical Events

A 2018 case report published in the British Journal of Anaesthesia described refractory intraoperative hypotension (MAP <50 mmHg for 12 minutes) in a patient who had self-administered intracavernosal alprostadil 40 mcg approximately 4 hours before general anesthesia for inguinal hernia repair [8]. Vasopressor rescue required phenylephrine 200 mcg bolus followed by norepinephrine infusion.

The FDA Caverject label explicitly warns: "Caverject should be used with caution in patients on antihypertensive agents, as concomitant use may increase the risk of hypotension" [1]. The same label lists syncope among adverse events in post-marketing surveillance.

Neuraxial Anesthesia Deserves Special Attention

Spinal and epidural blocks block T4-L2 sympathetics at doses used for urological or perineal procedures. Any residual alprostadil vasodilation may amplify the sympathectomy-induced hypotension. A 2020 review in Regional Anesthesia and Pain Medicine noted that pre-existing vasodilatory drug loads are an independent predictor of spinal hypotension severity in urological patients [7].

Specific Drug-Drug Interactions in the Perioperative Setting

Volatile Anesthetic Agents

Sevoflurane, desflurane, and isoflurane all dose-dependently reduce MAP. The 2019 Anesthesiology practice advisory on cardiovascular drug interactions categorizes PGE1 analogues alongside nitrates and calcium channel blockers as vasodilators requiring pre-operative reconciliation [5]. No randomized controlled trial has specifically paired alprostadil with volatile agents, but the mechanistic overlap is well established.

Propofol

Propofol causes vasodilation through inhibition of sympathetic tone and direct vascular smooth muscle relaxation. Its induction bolus (1.5 to 2.5 mg/kg IV) is the most hypotension-prone moment of any general anesthetic. Patients with detectable alprostadil exposure at induction are at amplified risk for MAP nadir events [6].

Alpha-Blockers (Tamsulosin, Alfuzosin, Silodosin)

Alpha-blockers are commonly co-prescribed in men with erectile dysfunction and benign prostatic hyperplasia. Alprostadil's FDA label specifically warns against concurrent alpha-blocker use, citing hypotension and priapism risk [1]. Perioperatively, alpha-blockers may be continued for urinary retention prophylaxis, the anesthesiologist must know the patient is also taking alprostadil.

Phosphodiesterase-5 Inhibitors (Sildenafil, Tadalafil, Vardenafil)

PDE5 inhibitors are absolutely contraindicated with nitrates but are also additive with alprostadil's vasodilation [9]. The Caverject label states alprostadil should not be combined with PDE5 inhibitors due to risk of priapism and hypotension [1]. Pre-operative medication reconciliation must confirm the patient stopped PDE5 inhibitors (sildenafil 24 hours; tadalafil 48 to 72 hours before surgery) independently of alprostadil hold.

Neuraxial Opioids

Intrathecal and epidural opioids contribute to peripheral vasodilation at high doses. Although their effect on vascular resistance is smaller than sympatholytics, stacking them on top of residual alprostadil activity adds to the hypotension burden [7].

Antihypertensive Agents

ACE inhibitors, angiotensin receptor blockers, and calcium channel blockers are the antihypertensives most often flagged for perioperative hypotension. The 2014 ACC/AHA guideline on perioperative cardiovascular evaluation recommends continuing beta-blockers but individualized management for RAAS agents [10]. When a patient also uses alprostadil, the combined vasodilatory load from a calcium channel blocker, an anesthetic agent, and residual PGE1 can be substantial, MAP monitoring at 1-minute intervals during induction is reasonable.

Can I Drink Alcohol on Alprostadil?

Alcohol and alprostadil should not be combined within the same dosing window. Ethanol is a vasodilator through endothelial nitric oxide release and direct smooth muscle relaxation. Alprostadil adds prostaglandin-mediated vasodilation through a distinct pathway. Together, they increase the likelihood of symptomatic hypotension, dizziness, and syncope [11].

The Caverject prescribing information does not state a formal alcohol contraindication, but it warns broadly that vasodilatory agents potentiate hypotension [1]. Clinically, most prescribers advise patients to avoid alcohol within 4 to 6 hours of any alprostadil dose.

Alcohol also impairs judgment about priapism recognition. Patients who drink after using Caverject may not notice or may delay reporting a persistent erection beyond the 4-hour threshold that defines a urological emergency [12].

Priapism Risk in the Perioperative Context

Priapism is a specific and underappreciated perioperative concern. Intracavernosal alprostadil carries an approximately 1% incidence of prolonged erection (>4 hours) in clinical trial data [1]. Drugs used perioperatively can alter this risk:

• Alpha-blockers: used for urinary retention prophylaxis, they reduce the sympathetic-mediated detumescence reflex, potentially extending erection duration [12].
• Anticoagulants and antiplatelet agents: heparin and aspirin used perioperatively do not directly cause priapism but complicate the aspiration/irrigation treatment if priapism occurs [13].
• Trazodone: sometimes prescribed for perioperative sleep or anxiety in older patients; trazodone alone carries a priapism risk and in combination with alprostadil this risk is compounded [12].

Any patient found to have a persistent erection on arrival to the surgical suite after self-administering alprostadil should have surgery delayed until the condition resolves; proceeding risks intraoperative detumescence with bleeding or proceeding with a partially ischemic penis [8].

Perioperative Management Protocol

The following stepwise approach reflects synthesized guidance from the FDA label, the ACC/AHA perioperative cardiovascular guideline [10], and anesthetic pharmacology literature [5] [6] [7]. It is intended for use by the surgical team during pre-operative assessment.

Step 1: Pre-operative Medication Reconciliation (7 to 14 Days Before Elective Surgery)

1. Ask specifically about erectile dysfunction medications. Many patients omit these unless directly asked.
2. Confirm which formulation: Caverject (intracavernosal) or MUSE (intraurethral). MUSE has higher systemic absorption.
3. Document last dose date and time.
4. Record concurrent PDE5 inhibitor, alpha-blocker, or antihypertensive use.

Step 2: Hold Alprostadil Before Surgery

For elective procedures under general or neuraxial anesthesia, hold alprostadil for at least 24 hours. Patients with renal impairment (eGFR <30 mL/min) or those using the intraurethral MUSE formulation should extend the hold to 48 hours given slower metabolite clearance [4].

For emergency surgery where hold is not possible:

• Alert the anesthesiologist to the recent dose and timing.
• Establish invasive arterial blood pressure monitoring.
• Prepare vasopressor infusion (phenylephrine or norepinephrine) before induction.
• Reduce induction agent dose by 20 to 30% and titrate to effect.

Step 3: Intraoperative Monitoring

• Continuous arterial line if the last alprostadil dose was within 6 hours.
• Non-invasive blood pressure every 1 minute during induction if the last dose was 6 to 24 hours prior.
• Target MAP >65 mmHg; treat any MAP <55 mmHg promptly with phenylephrine 50 to 100 mcg IV bolus [5].

Step 4: Post-operative Monitoring

Patients who used alprostadil within 24 hours of surgery should have a post-operative blood pressure check at 30 minutes and 60 minutes in the recovery room, particularly before any vasodilatory analgesics (ketorolac, morphine epidural top-ups) are administered.

Step 5: Resumption of Alprostadil After Surgery

There is no published randomized data on optimal restart timing. Standard clinical practice, per multiple institutional protocols, recommends waiting until:

• The patient is off vasopressor support.
• Oral intake is restored.
• At least 48 hours have passed from neuraxial anesthesia.

Special Populations

Renal Impairment

Alprostadil metabolites are renally excreted [4]. In patients with eGFR <30 mL/min, the pharmacodynamic half-life of the vasodilatory effect may extend well beyond the 60 to 90 minute window seen in healthy subjects. Dose reduction is recommended in the Caverject label for this population [1], and the perioperative hold should be extended to 48 hours.

Cardiovascular Disease

The ACC/AHA 2014 guideline identifies baseline left ventricular dysfunction (ejection fraction <35%) as a risk factor for perioperative hemodynamic instability [10]. Alprostadil-related vasodilation reduces afterload, which may actually be tolerated in mild heart failure but is dangerous in any state of volume depletion or fixed cardiac output (e.g., severe aortic stenosis). Patients with severe aortic stenosis should be counseled that alprostadil is relatively contraindicated regardless of surgical context [1].

Older Patients

Men over 65 are the primary demographic for alprostadil prescriptions. Age-related reductions in baroreceptor sensitivity mean older patients mount a slower compensatory heart rate response to vasodilatory hypotension. A 2021 analysis in Anesthesia and Analgesia found that patients over 65 had a 2.4-fold higher rate of induction hypotension compared with younger adults when taking two or more vasodilatory medications pre-operatively [6].

What the FDA Label Says

The FDA-approved Caverject prescribing information [1] contains several passages directly relevant to perioperative care:

"Patients on anticoagulant therapy such as warfarin or heparin may have increased propensity for bleeding after intracavernosal injection."

"Caverject should be used with caution in patients on antihypertensives, as concomitant use may potentiate the risk of hypotension."

The label does not name anesthetic agents specifically, but the antihypertensive warning extends logically to all vasodilatory drug classes used in anesthesia practice, as confirmed by the 2019 Anesthesiology practice advisory [5].

Evidence Base and Research Gaps

Most published evidence on alprostadil perioperative interactions is drawn from:

• The FDA Caverject label (based on Phase III trial data and post-marketing surveillance) [1].
• A small number of published case reports and series [8].
• Mechanistic pharmacology studies on PGE1 pulmonary extraction [3].
• General perioperative drug interaction guidelines that include vasodilatory drugs as a class [5] [10].

A 1996 study in the Journal of Urology (N=683) established baseline cardiovascular adverse event rates for alprostadil, finding hypotension in 0.6% of injections and dizziness in 2.0%, providing the denominator for perioperative risk estimates [14]. The MUSE intraurethral pellet trials (N=1,511) reported symptomatic hypotension in 3.3% of patients in outpatient settings, with no surgical or anesthetic co-exposure [2].

No randomized controlled trial has specifically examined alprostadil in the context of anesthesia. This is a genuine evidence gap. The clinical recommendations in this article derive from pharmacodynamic first principles, FDA labeling, perioperative guideline extrapolation, and case series.

Key Takeaways for Prescribers

Patients using alprostadil for erectile dysfunction represent a growing cohort as the population ages and surgical volumes rise. A 2020 analysis using Medicare data found that erectile dysfunction affects approximately 52% of men aged 40 to 70 [15], many of whom will require anesthesia for urological, cardiac, or general surgery.

Standard medication reconciliation forms often miss intracavernosal and intraurethral medications. Ask directly. The perioperative hold of 24 to 48 hours is short, simple to implement, and prevents the most serious risk, intraoperative hypotension that requires vasopressor rescue.

For emergency surgery, invasive arterial monitoring and a pre-drawn vasopressor are the two interventions most likely to prevent serious hemodynamic events in a patient with recent alprostadil exposure.